Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ALVO Alvotech	$9.23 +1.2%	$9.62	$7.35 ▼ $13.70	$2.78B	0.18	143,382 shs	48,163 shs
ARDX Ardelyx	$3.98 +1.4%	$3.99	$3.21 ▼ $7.18	$951.06M	0.6	4.82 million shs	1.83 million shs
KURA Kura Oncology	$5.87 +1.6%	$6.16	$5.41 ▼ $23.48	$507.73M	0.4	1.24 million shs	436,866 shs
SAVA Cassava Sciences	$1.87 +3.0%	$1.92	$1.15 ▼ $42.20	$90.05M	-2	2.97 million shs	524,647 shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ALVO Alvotech	-0.22%	-0.11%	-21.24%	-5.39%	-25.00%
ARDX Ardelyx	+6.23%	+7.99%	+5.38%	-18.16%	-47.10%
KURA Kura Oncology	+1.76%	-1.70%	+1.58%	-9.56%	-71.98%
SAVA Cassava Sciences	+3.43%	-4.23%	-10.84%	+31.16%	-85.34%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ALVO Alvotech	3.6919 of 5 stars	3.5	4.0	0.0	2.1	0.0	1.9
ARDX Ardelyx	4.2578 of 5 stars	3.5	3.0	4.4	1.5	2.5	0.6
KURA Kura Oncology	4.5495 of 5 stars	4.4	3.0	4.7	2.0	0.8	0.6
SAVA Cassava Sciences	4.2988 of 5 stars	3.3	3.0	4.7	2.7	0.8	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ALVO Alvotech	3.00	Buy	$18.00	95.12% Upside
ARDX Ardelyx	3.00	Buy	$10.89	173.93% Upside
KURA Kura Oncology	2.86	Moderate Buy	$24.50	317.73% Upside
SAVA Cassava Sciences	2.50	Moderate Buy	$54.50	2,822.25% Upside

Current Analyst Ratings Breakdown

Latest ALVO, KURA, SAVA, and ARDX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/26/2025	KURA Kura Oncology	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
6/20/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$36.00
6/18/2025	ARDX Ardelyx	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$10.00
6/4/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00
5/19/2025	KURA Kura Oncology	Mizuho Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$32.00 ➝ $30.00
5/2/2025	ARDX Ardelyx	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$11.00 ➝ $10.00
5/2/2025	ARDX Ardelyx	Raymond James Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Outperform	$11.00
5/2/2025	KURA Kura Oncology	Barclays Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$32.00 ➝ $11.00
4/29/2025	KURA Kura Oncology	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$28.00 ➝ $28.00
4/28/2025	KURA Kura Oncology	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$40.00 ➝ $40.00
4/8/2025	KURA Kura Oncology	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$36.00

(Data available from 7/1/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ALVO Alvotech	$491.98M	5.65	N/A	N/A	($1.37) per share	-6.73
ARDX Ardelyx	$333.61M	2.85	N/A	N/A	$0.73 per share	5.45
KURA Kura Oncology	$53.88M	9.42	N/A	N/A	$5.32 per share	1.10
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	$3.03 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ALVO Alvotech	-$231.86M	$0.37	24.93	46.13	N/A	16.42%	-36.37%	12.70%	8/21/2025 (Estimated)
ARDX Ardelyx	-$39.14M	-$0.22	N/A	12.82	N/A	-14.86%	-34.45%	-13.81%	7/30/2025 (Estimated)
KURA Kura Oncology	-$173.98M	-$2.10	N/A	N/A	N/A	N/A	-43.62%	-29.13%	8/6/2025 (Estimated)
SAVA Cassava Sciences	-$24.34M	-$1.50	N/A	N/A	N/A	N/A	-87.72%	-72.05%	8/6/2025 (Estimated)

Latest ALVO, KURA, SAVA, and ARDX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/8/2025	Q1 2025	SAVA Cassava Sciences	N/A	-$0.48	N/A	-$0.48	N/A	N/A
5/7/2025	Q1 2025	ALVO Alvotech	-$0.17	$0.35	+$0.52	$0.35	N/A	N/A
5/1/2025	Q1 2025	ARDX Ardelyx	-$0.10	-$0.17	-$0.07	-$0.17	$79.40 million	$74.11 million
5/1/2025	Q1 2025	KURA Kura Oncology	-$0.51	-$0.66	-$0.15	-$0.66	$39.08 million	$14.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ALVO Alvotech	N/A	N/A	N/A	N/A	N/A
ARDX Ardelyx	N/A	N/A	N/A	N/A	N/A
KURA Kura Oncology	N/A	N/A	N/A	N/A	N/A
SAVA Cassava Sciences	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ALVO Alvotech	N/A	1.73	1.19
ARDX Ardelyx	1.04	4.12	3.81
KURA Kura Oncology	0.02	8.07	8.07
SAVA Cassava Sciences	N/A	9.08	9.08

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ALVO Alvotech	N/A
ARDX Ardelyx	58.92%
KURA Kura Oncology	N/A
SAVA Cassava Sciences	38.05%

Insider Ownership

Company	Insider Ownership
ALVO Alvotech	N/A
ARDX Ardelyx	4.80%
KURA Kura Oncology	6.40%
SAVA Cassava Sciences	12.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ALVO Alvotech	1,032	301.48 million	N/A	Not Optionable
ARDX Ardelyx	90	239.26 million	227.77 million	Optionable
KURA Kura Oncology	130	86.57 million	81.03 million	Optionable
SAVA Cassava Sciences	30	48.31 million	42.41 million	Optionable

ALVO, KURA, SAVA, and ARDX Headlines

Recent News About These Companies

Cassava Sciences presents poster at TSC 2025 on Simufilam

June 30 at 7:14 PM | msn.com

Cassava Presents Promising Preclinical Simufilam Data at TSC Alliance Meeting

June 30 at 7:00 AM | globenewswire.com

SAVA Stock Price for Cassava Sciences Inc - Morningstar

June 28 at 11:21 PM | morningstar.comM

Why cassava could be a great addition to a balanced diet

June 26, 2025 | msn.com

Two Sigma Investments LP Has $1.33 Million Position in Cassava Sciences, Inc. (NASDAQ:SAVA)

June 5, 2025 | marketbeat.com

Two Sigma Advisers LP Invests $1.43 Million in Cassava Sciences, Inc. (NASDAQ:SAVA)

June 1, 2025 | marketbeat.com

Cassava gives AI firm access to its collection of GPUs

May 19, 2025 | htxt.co.zaH

Cassava gives AI firm access to its collection of GPUs

May 19, 2025 | htxt.co.zaH

Cassava partners with Zindi to give African AI developers better tools

May 15, 2025 | techzim.co.zwT

Cassava Sciences Inc.

May 15, 2025 | barrons.com

5 ON YOUR SIDE: Lead levels in cassava flour

May 15, 2025 | kstp.comK

Cassava Technologies, Zindi collaborate on AI services

May 12, 2025 | msn.com

Cassava Technologies and Zindi collaborate to showcase African A.I. innovation

May 12, 2025 | thezimbabwemail.comT

Cassava Technologies and Zindi Partner to Supercharge Africa’s AI and GPU Ecosystem

May 12, 2025 | devdiscourse.comD

New report finds concerning levels of lead in popular cassava items

May 12, 2025 | yahoo.com

Cassava takes next step for African AI

May 12, 2025 | htxt.co.zaH

Cassava Technologies and Zindi collaborate to showcase African Artificial Intelligence (AI) innovation

May 12, 2025 | zawya.comZ

Cassava Reports Q1 2025 Financials Results, Provides Business Update

May 9, 2025 | finance.yahoo.com

Zindi Teams Up with Cassava to Spotlight African AI Talent

May 6, 2025 | msn.com

Zindi Supports Cassava Technologies with 85 K Zindians to showcase African AI innovation

May 5, 2025 | msn.com

Cassava Consciousness from The Tamarind Galaxy part two

May 1, 2025 | modernghana.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ALVO, KURA, SAVA, and ARDX Company Descriptions

Alvotech NASDAQ:ALVO

$9.22 +0.11 (+1.15%)

As of 12:13 PM Eastern

Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. In addition, it offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an Entyvio product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an Keytruda product. Alvotech was founded in 2013 and is based in Luxembourg, Luxembourg.

Ardelyx NASDAQ:ARDX

$3.98 +0.06 (+1.40%)

As of 12:13 PM Eastern

Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor for the treatment of patients with irritable bowel syndrome with constipation. It also develops XPHOZAH, which is in Phase III clinical trial to reduce serum phosphorus in adults with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia; RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among patients with kidney and/or heart failure; and RDX020, for adult patients with metabolic acidosis, a serious electrolyte disorder. The company has agreements with Kyowa Kirin, Fosun Pharmaceutical Industrial Development Co. Ltd., and Knight Therapeutics, Inc. for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.

Kura Oncology NASDAQ:KURA

$5.86 +0.10 (+1.65%)

As of 12:13 PM Eastern

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification. The company was founded in 2014 and is headquartered in San Diego, California.

Cassava Sciences NASDAQ:SAVA

$1.86 +0.06 (+3.04%)

As of 12:13 PM Eastern

Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2 clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and changed its name to Cassava Sciences, Inc. in March 2019. Cassava Sciences, Inc. was incorporated in 1998 and is based in Austin, Texas.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time